HQ Function

Serves as a primary site for conducting ADME-Tox studies, including in vitro and in vivo assays, bioanalysis, and research and development for drug discovery programs. It houses advanced laboratory facilities and scientific expertise.

Notable Features:

State-of-the-art laboratories equipped for advanced ADME-Tox research, including high-resolution mass spectrometry, automated liquid handling systems, and facilities for radiolabeled compound studies. Recent expansions have increased capacity for in vitro ADME and PK studies.

Work Culture:

As a specialized CRO within the Symeres group, the culture emphasizes scientific rigor, precision, innovation, client-centricity, and collaboration. The environment fosters continuous learning and contribution to impactful drug development projects.

HQ Significance:

The Oulu site is a critical hub for Admescope's specialized ADME-Tox service delivery, leveraging Finland's strong life sciences ecosystem, skilled talent pool, and its established reputation for quality before and after the Symeres acquisition.

Values Reflected in HQ: The facilities and operations reflect a commitment to scientific excellence, cutting-edge technology, quality, reliability, and a collaborative approach to advancing pharmaceutical research and development.

Location:

While Admescope's physical laboratories are based in Oulu and Joensuu, Finland, it operates as a crucial part of Symeres, serving a global clientele across North America, Europe, Asia, and other regions. Symeres has a broader international presence with additional sites in the Netherlands, Czech Republic, Sweden, and the USA. Admescope's specialized ADME-Tox services support global drug discovery and development programs, providing critical data and expertise to pharmaceutical, biotechnology, and veterinary companies worldwide.

Street Address:

Tykistökatu 4 D

City:

Oulu

State/Province:

Northern Ostrobothnia

Country:

Finland